Delayed hypersensitivity to low molecular weight heparin (LMWH) in pregnancy

Elise Schapkaitz, barry frank jacobson


Heparin is currently the anticoagulant of choice for the prevention and treatment of thrombo-embolic disease in pregnancy because it does not cross the placenta [1]. The use of low molecular weight heparin (LMWH) is preferred to unfractionated heparin (UFH) as it is associated with a lower risk of bleeding, osteoporosis, heparin induced thrombocytopenia (HIT) and hypersensitivity reactions [2, 3, 4, 5]. Fondaparinux can be considered as a valuable alternative to LMWH during pregnancy in those patients with heparin induced skin reactions and/or HIT.

Authors' affiliations

Elise Schapkaitz, NHLS/WITS

barry frank jacobson, NHLS

Full Text

PDF (1431KB)


heparin; allergy

Cite this article

South African Medical Journal 2007;97(12):1255.

Article History

Date submitted: 2007-06-18
Date published: 2007-10-17

Article Views

Abstract views: 3179
Full text views: 2193

Comments on this article

*Read our policy for posting comments here